Imagine battling ovarian cancer, where every treatment decision could mean the difference between hope and heartbreak – but what if we're finally on the cusp of a breakthrough that personalizes therapies like never before?
Precision medicine in cancer care is all about hitting the right target for the best possible results, and that's exactly what a groundbreaking development in ovarian cancer treatment aims to achieve. Ovarian cancer, a sneaky and often deadly disease affecting the ovaries, has long challenged doctors with its complex nature. Currently, a class of drugs called PARP inhibitors – which work by blocking proteins that help cancer cells repair their DNA, making them more vulnerable to death – are typically given to patients whose tumors show a specific flaw in DNA repair, known as homologous recombination deficiency, or HRD for short. These patients are labeled 'HRD positive.'
But here's the twist that's been puzzling experts: not all women with HRD-positive tumors respond well to these inhibitors, and surprisingly, some with HRD-negative cancers do benefit. This suggests that other hidden factors, like immune responses or inflammation, play a crucial role in how effective the treatment really is. It's like trying to predict the weather with an outdated forecast – sometimes it works, but often it doesn't capture the full picture.
For years, clinicians have grappled with this uncertainty, knowing there had to be a better way to identify who would truly thrive on PARP inhibitors beyond the standard HRD test. Enter the SOLACE2 trial, led by brilliant minds at RMIT University and the Walter and Eliza Hall Institute (WEHI), which has uncovered a promising alternative: a simple blood test that gauges the body's immune activity. This test could revolutionize how we screen and treat patients, ensuring that only those most likely to benefit get the drug – potentially sparing others from unnecessary side effects and improving overall outcomes.
Distinguished Professor Magdalena Plebanski, the RMIT lead researcher and head of the Accelerator for Translational Research and Clinical Trials (ATRACT) Centre, shared her excitement: 'In SOLACE2, we've shown that this novel immune-based test outperforms the current HRD approach in predicting which women will respond to PARP inhibitors.' She envisions it as a game-changer for patient selection, allowing doctors to offer this cutting-edge therapy to those who need it most.
And this is the part most people miss – the test doesn't require invasive biopsies or complex genetic analyses. Instead, it measures key immune biomarkers in the blood that signal how well the body's good guys – cancer-fighting immune cells – are migrating toward and attacking tumor cells. It also looks at inflammatory processes that can fuel cancer growth and resist treatments. Together, these elements create a straightforward 'biomarker signature' from a routine blood draw, giving a real-time snapshot of the patient's immune battlefield. For beginners, think of it like a traffic report for your body's defenses: it shows if the reinforcements are arriving on time to battle the invaders.
The team's findings, detailed in a paper published in Nature Communications, highlight that their RMIT-patented markers, detectable via this easy blood test, might outshine the gold-standard HRD test. That said, it urgently needs further validation to confirm its reliability in broader settings. Why the urgency? The current HRD test often demands enough tumor tissue for detailed DNA analysis, which isn't always obtainable, and it might not reflect the cancer's changing DNA repair abilities over time – like a map that goes out of date as the terrain shifts.
'Our approach zeroes in on the live immune response in the blood,' Plebanski explained, 'rather than relying on the tumor's DNA status, which could be outdated. This helped us pinpoint SOLACE2 participants who would gain the most from PARP inhibitor therapy.'
But here's where it gets controversial – Professor Clare Scott AM, WEHI's lead researcher, joint-senior author, and head of the Ovarian and Rare Cancer Laboratory (as well as Chair of ANZGOG), emphasized a key discovery: the role of immune cells within the tumor itself in boosting PARP inhibitor success, especially when combined with other treatments. 'We saw that predicting if effector T cells – those frontline warriors of the immune system – can ramp up their entry into the tumor to start destroying cancer cells was a strong indicator of treatment response,' Scott noted. She's also a medical oncologist at top centers like Peter MacCallum Cancer Centre, the Royal Women’s Hospital, and Royal Melbourne Hospital. This insight opens doors to future therapies that could actively encourage immune cell migration, turning the body's defenses into even more potent allies. Yet, some might debate whether focusing on immune factors overshadows the genetic roots of cancer – is this a complementary tool or a potential replacement? The debate could reshape how we view cancer treatment hierarchies.
Of course, this innovative test isn't ready for prime time just yet. It requires more rigorous testing and regulatory approvals before it can be used in everyday clinical practice.
Diving into the SOLACE2 trial's broader results, Professor Chee Khoon Lee, clinical lead at the University of Sydney’s NHMRC Clinical Trials Centre and co-study chair, revealed that a three-month course of immune priming – essentially prepping the body's defenses – followed by PARP inhibitors and immunotherapy, effectively postponed ovarian cancer recurrences. 'Even with these positive results, the trial's modest size means we need larger studies to solidify its validity,' Lee cautioned. 'That being said, it did unveil this new test, which holds immense promise for tailoring treatments to individual women, maximizing effectiveness and minimizing risks.' For those new to this, immune priming is like warming up before a big game – it gets the immune system revved up and ready to fight harder.
What made this possible? A massive, coordinated effort across hospitals, orchestrated by ANZGOG, as highlighted by study co-author and RMIT Postdoctoral Research Fellow Dr. April Kartikasari. 'This kind of teamwork is vital for customizing therapies right at the first hint of recurrence, potentially transforming survival rates,' she said. 'PARP inhibitors are already a go-to first-line option for ovarian cancer, but with this blood test validated, we could better match them to responsive patients, elevating outcomes for countless women.'
Plebanski, who also directs RMIT’s Cancer, Ageing and Vaccines (CAVA) Laboratory in the School of Health and Biomedical Sciences, is thrilled about the progress but keeps her eyes on the horizon. 'This is a step toward immediate impact, yet our labs are pushing for long-term innovations, like novel drugs and vaccines that could end the cycle of cancer suffering altogether.'
In summary, this blood test represents a beacon of hope in the murky waters of ovarian cancer treatment, blending simplicity with precision to empower doctors and patients alike. But will it live up to the hype, or are there unforeseen challenges ahead? Do you think emphasizing immune markers over genetic tests is the future of personalized medicine? Could this spark ethical debates about who qualifies for advanced therapies? We'd love to hear your take – agree, disagree, or share your own experiences in the comments!
Reference: Lee CK, Kartikasari AER, Bound NT, et al. Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial. Nat Commun. 2025;16(1):9756. doi: 10.1038/s41467-025-64130-6 (https://doi.org/10.1038/s41467-025-64130-6)
This article has been republished from the following materials (https://www.rmit.edu.au/news/all-news/2025/jul/ovarian-cancer-test). Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here (https://www.technologynetworks.com/tn/editorial-policies#republishing).
